Thai Police Arrest Man for Illegal Sale of E-Cigarettes

Regulations by 2FIRSTS.ai

Dec.14.2023

Thai Police Arrest Man for Illegal Sale of E-Cigarettes

Thai police arrested Mr. Jenkij after seizing 70,000 e-cigarette devices worth over 10 million Thai Baht in a raid.

According to a report from Thailand's National Online on December 14th, on that same day, the Chief of the Thai Narcotics Suppression Bureau, Pol.Lt.Gen.Witthaya Sriprasertphap, ordered a series of consecutive raids on multiple apartments. Subsequently, they arrested a 32-year-old named Mr. Jenkij.

The operation began with the illegal sale of e-cigarettes and e-liquids on a Facebook page. Prior to purchasing e-cigarettes, the police examined the financial trail and found that the operation had a fund flow exceeding 100 million Thai Baht. After investigating the transportation routes and locations where the illegally concealed e-cigarette products were stored, they identified the storage site and conducted a search.

During the search, a total of 70,000 e-cigarette devices were discovered, with an estimated value exceeding 10 million Thai baht.

Therefore, the police have accused Mr. Jenkij of violating the provisions of the Thailand Consumer Protection Commission Order No. 9/2558 of 2015, which prohibits the sale or provision of e-cigarettes and e-liquids. They have also informed the Ministry of Commerce's statement, which categorizes e-cigarettes and e-liquids as goods that are not allowed to be imported into the kingdom (2014).

They confiscated the seized items and handed them over to investigators for legal proceedings.

References:

[1] ปคบ.ยึดบุหรี่ไฟฟ้าค่า 10 ล้านบาท จากแหล่งขายส่งผู้ค้ารายย่อย

Also Read:

[1] Thai Health Authority Warns of Increased Depression Risk from E-cigarettes

[2] Growing Threat of E-Cigarettes on Health in Thailand

#Law enforcement #Asia #Thailand #E-cigarette #E-cigarettes and Tobacco #Illegal e-cigarettes

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity

Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).

Sep.25 by 2FIRSTS.ai

KT&G Unveils lil hybrid 3.0 Misty Rose Limited Edition, Limited to 20,000 Devices

KT&G has launched the limited-edition “lil hybrid 3.0 Misty Rose Edition” heated tobacco device in South Korea, betting on year-end consumer demand with a gradient rose-colored design. The release is capped at 20,000 units and is available through both online and offline channels, with an official retail price of 78,000 won (approximately USD 53).

Nov.20 by 2FIRSTS.ai

Denver to Hold Referendum on Flavored Tobacco Sales Ban; If Approved, Enforcement Begins in 2026

A referendum to be held on November 4 will determine whether Denver retains its ban on the sale of flavored tobacco/nicotine products. Campaign finance records show that, as of the end of August, the side seeking to repeal the ban had raised $410,000, significantly more than the pro-ban side (about $245,000). The ban took effect in March 2025, but the city had planned to begin enforcement on January 2026; if the referendum overturns the ban, enforcement will not proceed.

Sep.25 by 2FIRSTS.ai

DARE Warns Malaysia: Vaping Bans Will Expand Illicit Market; Strengthen Enforcement Within Existing Framework

Malaysia’s policy think tank Datametrics Research and Information Sdn Bhd (DARE) cautions that state- or nationwide bans on e-cigarettes would fuel the illicit market, weaken investor confidence, reduce tax revenues, and cost jobs. DARE argues that authorities should prioritize consistent enforcement under existing laws rather than impose new prohibitions.